By Professor Nancy Ip
President, The Hong Kong University of Science and Technology
The future of human health will not be written by a single nation or institution, but through the collective intelligence and shared ambition of global partnerships. In an era defined by complex health challenges, from the growing prevalence of neurodegenerative diseases to the need for equitable healthcare, the world requires new models of collaboration that bridge continents, cultures, and capabilities. Today, a particularly powerful alliance is emerging on the horizon, one that holds the potential to reshape the life sciences landscape: the partnership between Hong Kong and the Kingdom of Saudi Arabia.
Saudi Arabia’s bold Vision 2030, anchored by its National Biotechnology Strategy, issues a clarion call for a new kind of global partnership in science. This vision powerful echoes Hong Kong’s own quest to become a premier international innovation and technology hub. His Excellency Eng. Abdulaziz Alrumaih’s powerful statement at BIO 2025—that the Kingdom is “here not just to observe but to lead”—finds a natural and strategic partner in Hong Kong. We are complementary engines of discovery, and by uniting our strengths, we can accelerate a new wave of biomedical breakthroughs for the benefit of our societies and the world.
Saudi Arabia’s vision: Building the ecosystem of tomorrow
The Kingdom’s strategy is both comprehensive and astute. Its focus on developing end-to-end vaccine manufacturing, establishing biomanufacturing for biologics and biosimilars, expanding a national genomic database, and optimizing plant biotechnology addresses the entire value chain, from foundational research to commercial scalability and societal impact.
Crucially, the Kingdom’s approach, as articulated by Vice Minister AlRamaih, is built on principles that mirror the ethos of any successful innovation ecosystem: enabling an integrated, end-to-end pipeline; balancing long-term vision with immediate action; and advancing a digitally powered infrastructure. The “Biotech Accelerator” program, designed to empower Saudi innovators and connect them to global markets, is a prime example. This is where Hong Kong’s unique value proposition comes into sharp focus.
Hong Kong’s proven track record: Engineering the future of health
Hong Kong has spent decades cultivating a world-class ecosystem for the life sciences, distinguished by a unique fusion of fundamental research, cutting-edge engineering, and a dynamic innovation pipeline. The Hong Kong SAR Government’s InnoHK initiative has been pivotal in establishing research clusters that are at the forefront of healthcare technologies. A shining example is the Hong Kong Center for Neurodegenerative Diseases, which builds upon the pioneering work of HKUST’s State Key Laboratory of Nervous System Disorders.
At HKUST, we have long championed a convergent approach where biology, AI, and engineering intersect. This philosophy is the bedrock of our impact. Our researchers are pioneering AI systems that deliver comprehensive cancer diagnoses and developing medical imaging technology that slashes radiation exposure by 99%, a testament to how AI can make healthcare both safer and more accessible. We are also engineering the very tools of discovery and treatment, from the world’s smallest multifunctional biomedical robot for interventional diagnosis to smart devices for surgical assistance and rehabilitation.
A pivotal moment in our journey, and for Hong Kong’s healthcare future, is the recent approval by the HKSAR Government for HKUST to establish the city’s third medical school. With future-ready biomedical and medical care central to our strategy, the HKUST School of Medicine (SMED) is poised to advance the city’s healthcare system. It represents a fundamental reimagining of medical education for the 21st century. Leveraging our scientific and technological strengths (we are ranked 17th globally in data science and AI), we will train a new generation of tech-savvy clinicians in partnership with government, industry, and the city’s established medical schools. This school will be engineered from the ground up to be the ultimate translational platform, ensuring breakthroughs in AI and engineering are rapidly incorporated into patient care. Its momentum is already clear, with nearly 40 agreements secured with leading medical institutions across Hong Kong, the Greater Bay Area and other regions of Mainland China, the UK, the US, and Europe. This powerful new initiative perfectly complements our established strengths and provides a dynamic hub for global collaborations.
The synergy: A blueprint for collaboration
The alignment between Saudi Arabia’s strategic goals and Hong Kong’s proven capabilities creates a powerful blueprint for collaboration. Our partnership can be built on four key pillars:
- Joint R&D and Talent Cultivation: Saudi Arabia’s focus on genomic databases and preventive healthcare is a perfect match for Hong Kong’s expertise in AI-driven diagnostics and therapeutic research. We can establish joint research laboratories, focusing on areas of mutual priority such as precision medicine for populations in Asia and the Middle East. The HKUST School of Medicine can serve as a nexus for developing exchange programs with Saudi Arabia’s institutions, cultivating a transnational cohort of physician-scientists who are fluent in both technology and medicine.
- Bridging the biomanufacturing gap: The Kingdom’s ambition to become a biomanufacturing powerhouse requires not just production capacity, but intelligent, AI-driven systems to optimize it. This is a core strength at HKUST, where we are engineering the future of bioprocessing. Our researchers develop smart sensors and AI models for real-time monitoring and control of bioreactors, a critical step in ensuring the quality and yield of complex biologics. Furthermore, our work in robotics points to our capability in pioneering the automated, high-precision systems that next-generation biomanufacturing demands.
- Accelerating commercialization: The synergy between Saudi Arabia’s “Biotech Accelerator” program and Hong Kong’s status as a global financial center is a powerful catalyst for commercialization. Imagine a joint “sandbox” where Saudi innovators plug directly into Hong Kong’s venture capital, legal, and regulatory ecosystems. This vision is achievable through initiatives such as the Hong Kong Biotechnology Fund, launched by HKUST with the explicit goal of cultivating and commercializing breakthroughs by bridging academia and industry. Together, we can deploy this model to propel joint ventures from the lab to the global marketplace.
- Pioneering digital health and regulatory science: Both our regions emphasize digitally powered infrastructure. We can collaborate on setting international standards for data privacy and interoperability in health tech, thus creating a trusted framework for the exchange of anonymized genomic and health data. This would not only accelerate research but also position both Hong Kong and Saudi Arabia as thought leaders in the ethical governance of digital medicine.
A statement of shared intent
When Vice Minister Alramaih stated: “We are investing in our future, partnering with the world’s best,” he defined a threshold of excellence that Hong Kong is primed to meet. We are not merely observers of this transformative period; we are active architects. Hong Kong offers Saudi Arabia a tested model of success, a gateway to the vast Asian markets, and a deep reservoir of scientific and engineering talent, now amplified by our pioneering venture in tech-infused medical education.
Our shared ambition extends beyond creating individual companies or products toward a larger goal: building a transcontinental corridor for life sciences innovation. This partnership is a statement of shared intent and a commitment to ensuring that the fruits of scientific progress transcend geography to build thriving, healthy societies, as envisioned by both Saudi Vision 2030 and Hong Kong’s innovation-driven future. Let us now begin this ambitious journey, turning collaboration into innovation, and innovation into lasting global impact.
